Atomo Diagnostics’ AtomoRapid(TM) HIV Device, designed by ide, Named Best-in-Show Winner at 2014 Medical Design Excellence Awards

SYDNEY / PRNewswire/ — ide, a new product development group, announced today that the AtomoRapid™ HIV device designed and developed by ide under contract with Atomo Diagnostics, a medical technology company, was selected as the “Best-in-Show” winner at the 2014 Medical Design Excellence Award (MDEA). The device also won the Gold award for the In Vitro Diagnostic Products and Systems category. Both Atomo Diagnostics and ide were honoured at a ceremony held June 11, 2014 at the MD&M East, part of MedTechWorld in New York, N.Y.

AtomoRapid™ HIV is the world’s first integrated rapid HIV blood test, offering a simple, reliable solution for diagnosing HIV in the field and is currently being marketed in South Africa by Atomo Diagnostics.

Atomo Diagnostics is now working with USA industry partners and investors on market entry for the AtomoRapid blood test device for a range of medical conditions including celiac disease and allergies through to infectious diseases such as malaria and HIV.

“With the increasing demand in the healthcare industry for devices that are lower cost, faster, more convenient, and most importantly, accurate, AtomoRapid™ HIV is truly a groundbreaking device,” said Richard Sokolov, product development director at ide. “We are honoured to receive this prestigious industry award with our partner, Atomo Diagnostics, and to be recognised for the impact that this device will have in not only diagnosing HIV around the world, but also other serious diseases.”

“ide worked with us throughout the commercialisation process — through discovery, design, manufacturing, and launch,” said John Kelly, CEO of Atomo Diagnostics.” Their constant focus on excellence innovation and the quality of the user experience has helped us launch a product that’s truly disruptive in the diagnostic healthcare market.”

In 2013, ide’s ResMed Pixi Pediatric Mask was selected as a MDEA Finalist. MDEA is the Medtech industry’s premier design competition recognising the achievements of medical device manufacturers, their suppliers, and the many people behind the scenes — engineers, scientists, designers, and clinicians — who are responsible for groundbreaking innovations that are saving lives; improving patient healthcare; and transforming medtech worldwide — one innovation at a time.

About Atomo Diagnostics

Atomo Diagnostics is an ISO 13485 medical technology company with a range of integrated and award-winning products for use in rapid diagnostic blood testing. Patients rely on dependable and accurate testing and through collaborative commercialisation the AtomoRapid™ technology has been developed to meet these patient requirements, irrespective of the test. For more information on the company, visit: www.atomodiagnostics.com.

About ide

ide is an innovative developer of award-winning products that are impacting the pharmaceutical, medical device and consumer industries. As an ISO 9001 and ISO 13485 certified company, ide provides design, engineering, new product implementation, and manufacturing management services to help its partners solve the hard challenges and bring their products to life.  With offices in Sydney, Australia and Hershey, Pennsylvania, and contract manufacturing partners in Shenzhen, China, ide can also be found online at: www.idegroup.com.au or on Twitter at @ide_group.

Source: ide

Kingyoup Unveils High Throughput Semiconductor Wafer Bonding & Debonding Tool at ECTC 2014

NEW TAIPEI CITY/PRNewswire/ — Kingyoup Optronics Co., Ltd. (“Kingyoup”) during the IEEE Electronics Components and Technology Conference (ECTC) held at Orlando, Florida USA, in May 2014 show-cased their temporary bonding and debonding equipment developed in collaboration with IBM (NYSE:IBM). This equipment is specially designed to meet the microelectronics miniaturization needs of today’s smart, mobile, consumer electronics devices. Specifically, it enables 3D Integrated Circuits, 2.5D Packaging Integration and System applications.

The temporary bonding and debonding equipment uses a hybrid laser debonding solution with an industry-leading throughput of over 60 to 100 wafers per hour. It also supports wafer thinning to less than a human hair thickness (<< 50 um ) for either 200mm or 300mm wafers. A video demonstration of the debonding equipment releasing wafers was shown at the ECTC exhibit booth.

Working together with IBM, Kingyoup has developed a solution that demonstrates lower power consumption and much faster wafer cleaning, leading to high yield and high throughput, and concludes with lower cost of ownership.

Technical presentations by IBM researchers discussed the benefits of this patented laser debonding technology.  The technology can be applied to semiconductor wafer processing and packaging technologies in either wafer level or panel size formats.

About Kingyoup Optronics

Kingyoup Optronics(KYO), founded and invested by Kingyoup Enterprises in 2013, is an expert in design and manufacturing of in-line sputter equipment, roll to roll sputter equipment and 3D IC wafer bonder and debonder.

Facing rapid growth of end products requiring high performance and miniaturization design, 2.5D, 3D and fan out IC packaging solutions have become one of the key technologies in semiconductor industries. With IBM technology licensing, Kingyoup is now designing mass production wafer bonding and laser debonding equipment. Beta tool is available for live demo. Furthermore, temporary bonding and de-bonding also could be applied in the process of light weight and wearable device in the future.

KYO has rich experiences in touch panel sputtering and FPD industry. We provide total solution for ITO, SiO2, Metal, Nb2Ox coating…etc., and we record outstanding sales performance of 3.5G to 7.5G in-line sputter equipment. KYO is one of the few suppliers in Taiwan and China who is capable of coating of multi-layer film. KYO also has delivered roll to roll equipment for high-end flexible material and process. Visit KYO website at:www.kyopt.com

Media Contact

Baker Tu
Financial Director of KYO
+886-2-2999-1355 ext:141
baker.tu@kingyoup.com

Source: Kingyoup Optronics Co., Ltd.

Related stocks: NYSE:IBM

Sanofi to Present New Clinical Data at American Diabetes Association 74th Scientific Sessions

• New results for Toujeo^® (insulin glargine [rDNA origin] injection, 300 U/mL; “U300”) from EDITION I/II/III meta-analysis, EDITION III, IV, JP 1 and JP 2 studies are among over 65 abstracts to be presented

PARIS, June 11, 2014 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that new data on U300, Lyxumia^® (lixisenatide) and Lantus^® will be presented at the American Diabetes Association (ADA) 74^th Scientific Sessions in San Francisco, June 13‒17. Abstracts are available on the ADA website.

Eight abstracts from the EDITION Phase III program for U300 will be presented. The worldwide and comprehensive EDITION program evaluated, in broad and diverse populations of people with diabetes, the efficacy and safety of U300 vs. Lantus^®. Following presentation of EDITION I^[1] and II^[2] results in 2013, a meta-analysis of EDITION I/II/III; full results from the other four studies in the EDITION program; and year one results from EDITION I and II showing the first longer-term data for U300, will be presented at ADA 2014.

More than 55 additional abstracts from across the Sanofi Diabetes portfolio will also be presented. Data highlights from lixisenatide, the fixed-ratio combination of lixisenatide and Lantus^®, Lantus^®, and the TEENs study are listed below.

Data highlights

• Abstract # 90-LB: New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-analysis of Phase 3a EDITION Clinical Trials in People with T2DM
• Abstract # 68-OR: New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Insulin Naïve People with T2DM (EDITION 3)
• Abstract # 80-LB: Glycemic Control and Hypoglycemia with New Insulin Glargine 300U/mL in People with T1DM (EDITION 4)
• Abstract # 88-LB: New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Japanese People with T1DM (EDITION JP 1)
• Abstract # 94-LB: Glycemic Control and Hypoglycemia in Japanese People with T2DM Receiving New Insulin Glargine 300 U/mL in Combination with OADs (EDITION JP 2)
• Abstract # 81-LB: Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal + Mealtime Insulin (EDITION 1)
• Abstract # 93-LB: Less Nocturnal Hypoglycemia and Weight Gain with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal Insulin with OADs (EDITION 2)
• Abstract # 892-P: Low Within- and Between-Day Variability in Exposure to New Insulin Glargine 300 U/mL
• Abstract # 919-P: New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM

Data highlights

16 abstracts (including 1 publication-only) will be presented on lixisenatide, including:

• Abstract # 1017-P: Effect of Lixisenatide vs. Liraglutide on Glycemic Control, Gastric Emptying, and Safety Parameters in Optimized Insulin Glargine T2DM ± Metformin
• Abstract # 118-LB: Effectiveness of Lixisenatide Before Breakfast or the Main Meal Using CGM with AGP Analysis

2 abstracts will be presented on the fixed-ratio combination of lixisenatide and Lantus^®, including:

• Abstract # 332-OR: Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin

27 abstracts will be presented on Lantus^®, including:

• Abstract # 6-LB: Enhanced Prediction of Cardiovascular Events By Adding Novel Biomarkers to Clinical Risk Factors in the ORIGIN Trial

3 abstracts for the first global presentation of the TEENs study results will be presented, including:

• Abstract # 32-OR: Global Assessment of Factors Associated with Target Glycemic Control in Youth with Type 1 Diabetes (T1D): the TEENs Study

About Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)

Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL; “U300”) is a new basal insulin currently in development for the treatment of people with diabetes mellitus. U300 has a pharmacokinetic and pharmacodynamic profile with studies demonstrating it is smoother and more prolonged than Lantus®.[3-6] Toujeo® is the intended trade name for U300. U300 is not currently approved or licensed anywhere in the world.

About Lyxumia® (lixisenatide)

Lyxumia® (lixisenatide) is a once-daily prandial glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal. It is known to suppress glucagon secretion from pancreatic alpha cells and stimulate glucose-dependent insulin secretion by pancreatic beta cells.

Lyxumia was in-licensed from Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL),http://www.zealandpharma.com and was approved in Europe in 2013 for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control. Lyxumia is currently approved in over 40 countries worldwide for the treatment of adults with type 2 diabetes, with commercial launches in Europe, Japan, Mexico and other markets. Sanofi plans to resubmit the New Drug Application for lixisenatide in the United States in 2015, after completion of the ELIXA cardiovascular outcomes study. Lyxumia is the proprietary name approved by the European Medicines Agency and other health authorities for the GLP-1 RA lixisenatide.

The Lyxumia pen is the winner of the Good Design Award 2012 and the iF Product Design Award. The variant of the Lyxumia pen used in Japan won the Good Design Award (G Mark) 2013.

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

References

1. Riddle M, et al. New insulin glargine formulation: glucose control and hypoglycaemia in people with type 2 diabetes using basal and mealtime insulin (EDITION I). Diabetologia. 2013;56 (Suppl 1):A220.
2. Yki-Jarvinen et al. An investigational new insulin U300: glucose control and hypoglycemia in people with type 2 diabetes on basal insulin and OADs (EDITION II). Abstract at World Diabetes Congress 2013. Oral presentation OP0075 Abstract.
3. Dahmen R et al New Insulin Glargine U300 Formulation Evens and Prolongs Steady State PK and PD Profiles During Euglycemic Clamp in Patients With Type 1 Diabetes (T1DM). 73rd Scientific Sessions of the ADA, abstract no. 113-OR.
4. Tillner J, et al. Euglycaemic single dose clamp profile of new insulin glargine formulation in subjects with type 1 diabetes is flat and prolonged.Diabetologia. 2013;56 (Suppl 1):A1033.
5. Jax T, et al. New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes. Diabetologia. 2013;56 (Suppl 1):A1029.
6. Shiramoto M, et al. Single dose of new insulin glargine Gla-300 formulation has a flatter and prolonged PK/PD profile than Gla-100 in Japanese subjects with type 1 diabetes. Diabetologia. 2013;56 (Suppl 1):A1031.

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Source: Sanofi Diabetes

Coming Soon: 12th Annual ‘Nano Korea 2014’ — the Country’s Largest Nano Convergence Exhibition

‘Nano Korea 2014,’ the world’s 2^nd largest with 360 companies from 12 countries, to be held at COEX for 3 days from July 2

SEOUL, South Korea, June 11, 2014 /PRNewswire/ — Nano Korea 2014, the 2^nd largest cutting-edge technology exhibition in the world, will be held in the exhibition hall on the 1^st floor of COEX in Seoul for 3 days from July 2 (Wed) to July 4 (Fri). This year promises to be bigger than ever with a total of 520 booths of 360 companies. Hosted by the Ministry of Trade, Industry & Energy, and supervised by the Ministry of Science, ICT & Future Planning, Nano Korea is the country’s premier international event for the nano convergence industry that has been held annually since 2003.

For 2014, in addition to the large number of displays featuring state-of-the-art technologies and products to which nano technology can be applied, there will be 6 additional new technologies featured including micro/MEMS, advanced ceramics, lasers, 3D printers and bionics. So, there will be more attractions than ever.

In the “Nano Korea” exhibition, 360 or so companies and organizations including large domestic and overseas companies, SMEs, venture firms, research institutes and universities related to nano technology will introduce the latest nano technologies and applied products as well as their research results.

This year, large corporations such as Samsung and LG will exhibit real products that combine IT & electronics, semiconductors and displays with current nano technology. They are also planning to unveil a variety of technologies and concept products, including functional coating solutions, conductive inks and CNT solutions.

It appears that nano institutions and corporations from 13 foreign countries, including the US, Japan, China and Iran, will also participate and introduce their outstanding nano technologies and use the exhibition as an important bridgehead for making inroads into the Korean market.

“The only nano convergence exhibition in the country, Nano Korea will provide practical business opportunities to diffuse nano technology research results and exchange information,” said a Nano Korea Organizing Committee official. “We will do our best to invigorate the exchange of technologies and products between Korean and foreign companies by cooperating with overseas institutions, which is the biggest strength of Nano Korea.”

For more details, visit www.nanokorea.or.kr

Source: NANO KOREA 2014 Exhibition Secretariat

SingTel Ranked #1 In Singapore

SINGAPORE/PRNewswire/ — Today, Alpha Southeast Asia revealed the results of their fourth annual poll to find Southeast Asia’s top companies.  The awards are based on tallied votes among 477 investors, pension funds, hedge funds, equity and fixed income brokers and analysts with investment interests in the Southeast Asia region. Listed-companies in Thailand, Singapore, Malaysia, Indonesia and the Philippines were ranked according to institutional investors’ perceptions of their performance in financial management, adherence to corporate governance, integrated reporting/ CSR and investor relations’ strategy.

In Singapore, six companies considered creme de la creme by institutional investors included regional diversified telecoms company SingTel, aspiring global real estate player CapitaLand, regional banks DBS Bank and OCBC, conglomerates SembCorp and Keppel Corp.

Ms. Chng Sok Hui, CFO, DBS Bank was voted as the Best CFO in Singapore.

Across the region, the award for the Strongest Commitment to Sustainable Energy in Southeast Asia went to leading integrated energy company Thai Oil for the third consecutive year. Best CFO in Southeast Asia went to Bank Mandiri’s Group CFO Pahala Mansury, responsible for managing the financial resources of its growing domestic and regional footprint.

Contrarily, Blumont, Asiasons & LionGold, Keppel Land and Overseas Union Enterprise were noted by investors for “perceived” poor management practices and unpredictable investor relations’ strategy.

Results for Singapore are as follows (according to most # of votes):

• Most organized investor relations (IR): SingTel (#1), CapitaLand (#2), SembCorp Industries (#3)
• Best Senior Management IR Support: SingTel (#1), CapitaLand (#2), SembCorp Industries (#3)
• Strongest Adherence to Corporate Governance: SingTel (#1), CapitaLand (#2), Keppel Corp (#3)
• Most Consistent Dividend Policy: SingTel (#1), DBS Bank, (#2), OCBC (#3)
• Best Strategic CSR: SingTel (#1), CapitaLand (32), DBS Bank(#3)
• Most Improved Investor Relations: SembCorp Industries
• Best CFO in Singapore: Chng Sok Hui, CFO, DBS Bank
• Best Annual Report in Singapore: DBS Bank

Guggenheim UBS MAP Global Art Initiative Travels To Latin America

– Museu de Arte Moderna in Sao Paulo, Brazil, and Museo Jumex in Mexico City, Mexico, to Host Under the Same Sun: Art from Latin America Today

– Curated by Pablo Leon de la Barra, Under the Same Sun examines the most significant contemporary art practices in Latin America today.

NEW YORK, June 12, 2014 /PRNewswire/ — The Solomon R. Guggenheim Foundation and Museum today announced that Under the Same Sun: Art from Latin America Today, the second exhibition of the Guggenheim UBS MAP Global Art Initiative, will travel to the Museu de Arte Moderna (MAM) in Sao Paulo, Brazil, from April to June, 2015, and the Museo Jumex in Mexico City, Mexico in Fall 2015, following its presentation at the Solomon R. Guggenheim Museum from June 13 to October 1, 2014. Organized by Pablo Leon de la Barra, Guggenheim UBS MAP Curator, Latin America, Under the Same Sun examines the most significant contemporary art practices in Latin America today. The Museu de Arte Moderna is one of the leading modern and contemporary art museums in Brazil and has been a pioneer in education in museums in the country. The Museo Jumex is part of the Fundacion Jumex Arte Contemporaneo, which was established to promote the production, analysis, and research of contemporary art, and to develop new ways to support art and culture.

Photo – http://photos.prnewswire.com/prnh/20140611/117099

Richard Armstrong, Director of the Solomon R. Guggenheim Museum and Foundation, stated: “We are very pleased to be working with two very distinguished institutions on the second phase of the Guggenheim UBS MAP Global Art Initiative: the Museu de Arte Moderna in Sao Paolo and the Museo Jumex in Mexico City, Mexico. The great strength of this multifaceted collaboration is that it enables us to go beyond the walls of our museums and engage with artists, curators, educators and the public across a vast part of the world, including Latin America.”

Milu Villela, President of the Museu de Arte Moderna de Sao Paulo, declared: “We are honored to receive the new collection of Latin American art from the Solomon R. Guggenheim Museum and Foundation, which will offer a contemporary reflection on our regional culture to the Brazilian public. Collaborating with an institution of such global relevance will also bring new perspectives on the educational activities in museums, which is a fundamental aspect of our mission.”

Patrick Charpenel, Director of the Museo Jumex stated: “For Fundacion Jumex Arte Contemporaneo, it is particularly important to present a project concerning Latin American art at Museo Jumex. Through the leadership of the Solomon R. Guggenheim Foundation and Museum and the broad vision of Pablo Leon de la Barra, Guggenheim UBS MAP Curator, Latin America, the MAP initiative is launching a program of activities that will increase dialogue among cultural agents in Central and South America.”

The New York presentation of Under the Same Sun features nearly fifty contemporary works by forty artists and collaborative duos representing fifteen countries, including Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Guatemala, Honduras, Mexico, Panama, Peru, Puerto Rico (United States), Uruguay, and Venezuela.

For each of the presentations at MAM and Museo Jumex, Pablo Leon de la Barra and the Guggenheim team will collaborate with museum staff to customize the exhibition for the local audiences. In addition, education leaders from each institution will work together to create tailored materials for students and the general public both at the museum and online.

Guggenheim UBS MAP Global Art Initiative is a collaboration between the Solomon R. Guggenheim Foundation and financial services firm UBS.

About Guggenheim UBS MAP Global Art Initiative
Inaugurated in April 2012, the Guggenheim UBS MAP Global Art Initiative is a multiyear collaboration that charts contemporary art practice in three geographic regions — South and Southeast Asia, Latin America, and the Middle East and North Africa — and encompasses curatorial residencies, international touring exhibitions, audience-driven education programming, and acquisitions for the Guggenheim’s permanent collection. All works have been newly acquired for the Guggenheim’s collection under the auspices of the Guggenheim UBS MAP Purchase Fund. The initiative builds upon and reflects the Solomon R. Guggenheim Foundation’s distinguished history of internationalism and significantly increases the Guggenheim’s holdings of art from these dynamic communities. Learn more at guggenheim.org/MAP.

Source: Solomon R. Guggenheim Foundation